跳到正文
研踪PaperTrail
← 研踪 PaperTrail

arXiv:2611.19339 · v1

From Mutation to Medication: Characterizing Failures of Clinical LLMs to Respect Genomic Resistance

首次提交 2026-11-14 19:26
版本更新 2026-11-14 19:26
雷达观测 2026-11-17 12:06
arXiv ↗PDF ↗

摘要

Language models are increasingly proposed to support molecular tumour boards, but may recommend cancer therapies despite genomic evidence of resistance. We evaluated ten models on 1,464 resistance cases from five curated oncology knowledge bases, collecting 58,910 judgments. Models endorsed resisted therapies in 21.8-81.4% of cases. However, raw rates can reflect a tendency to agree rather than an ability to distinguish resistance from drug sensitivity: one open-weight model endorsed 81.4% of resistance cases and 82.3% of sensitivity controls. We therefore compared endorsement within matched gene and evidence-level groups. This analysis is exploratory because it was specified after the pre-registered analysis, which yielded null-to-weak results. Measured failures depended strongly on the reference knowledge base and evidence strength. When a second source independently confirmed resistance, four models across three vendors endorsed at most 2.4% of cases; at weaker evidence tiers, discrimination was not measurable. Models sometimes acknowledged resistance yet recommended the therapy. Repeating a model's own resistance conclusion reduced endorsement to 0.0-3.5% on cases where it had stated resistance. Falsely attributing the opposite conclusion increased endorsement above baseline for all seven hosted models, reaching 95.2% for GPT-4o; an instruction without an attributed conclusion changed endorsement by only 0.9 percentage points. Providing the correct curated evidence reduced unqualified strong recommendations to 0.3-3.5%, testing evidence use under an oracle condition rather than retrieval.

作者备注:Accepted for publication in the Proceedings of the Machine Learning for Health (ML4H) 2026 Symposium

AI 论文解读

基于摘要 · 非全文审阅

此版本尚未生成 AI 解读。解读由后台任务生成并按论文版本保存,登录后共享已有结果。

版本差异

目前只收录了一个版本。收录下一版后,可以对照标题、作者、分类和摘要。

观测到的版本

相邻记录可能跳过中间版本;首次发现 v2 及以上也会标为版本更新。

v1 · 2026-11-14 19:26 · 最新观测版本

From Mutation to Medication: Characterizing Failures of Clinical LLMs to Respect Genomic Resistance

Language models are increasingly proposed to support molecular tumour boards, but may recommend cancer therapies despite genomic evidence of resistance. We evaluated ten models on 1,464 resistance cases from five curated oncology knowledge bases, collecting 58,910 judgments. Models endorsed resisted therapies in 21.8-81.4% of cases. However, raw rates can reflect a tendency to agree rather than an ability to distinguish resistance from drug sensitivity: one open-weight model endorsed 81.4% of resistance cases and 82.3% of sensitivity controls. We therefore compared endorsement within matched gene and evidence-level groups. This analysis is exploratory because it was specified after the pre-registered analysis, which yielded null-to-weak results. Measured failures depended strongly on the reference knowledge base and evidence strength. When a second source independently confirmed resistance, four models across three vendors endorsed at most 2.4% of cases; at weaker evidence tiers, discrimination was not measurable. Models sometimes acknowledged resistance yet recommended the therapy. Repeating a model's own resistance conclusion reduced endorsement to 0.0-3.5% on cases where it had stated resistance. Falsely attributing the opposite conclusion increased endorsement above baseline for all seven hosted models, reaching 95.2% for GPT-4o; an instruction without an attributed conclusion changed endorsement by only 0.9 percentage points. Providing the correct curated evidence reduced unqualified strong recommendations to 0.3-3.5%, testing evidence use under an oracle condition rather than retrieval.

查看此版本解读 →查看此版本原文 ↗